alexa Unbalanced reporting of benefits and harms in abstracts on rofecoxib.
Genetics & Molecular Biology

Genetics & Molecular Biology

Journal of Tissue Science & Engineering

Author(s): Jrgensen AW, Jrgensen KJ, Gtzsche PC

Abstract Share this page

Abstract PURPOSE: It was predicted from the mechanism of action that, compared to older non-steroidal anti-inflammatory drugs, rofecoxib (Vioxx) would reduce gastrointestinal bleeding, but also that it would increase the occurrence of cardiovascular thrombosis. From the patient's point of view, both effects are important and should be investigated and reported similarly. We studied how they have been reported over time. METHODS: We searched PubMed for abstracts on rofecoxib that commented on gastrointestinal bleeding or cardiovascular thrombosis or both. Two researchers, blinded to date of publication and authors, assessed the abstracts independently. We judged the authors' view on rofecoxib and comments on gastrointestinal bleeding and thrombosis as being favourable, neutral or unfavourable towards rofecoxib. RESULTS: We included 393 abstracts commenting on gastrointestinal bleeding (72\%) and cardiovascular thrombosis (54\%) or both. Before October 2000, all abstracts (n = 27) mentioned only gastrointestinal bleeding and 89\% were positive towards rofecoxib. The year before the withdrawal of rofecoxib (October 2003 to September 2004) (n = 46), 59\% of abstracts commented on gastrointestinal bleeding only, 17\% on thrombosis only, 24\% on both and 67\% were still positive. From October 2006 to September 2007 (n = 54), 13\% mentioned gastrointestinal bleeding, 54\% thrombosis, 33\% mentioned both and only 11\% were positive. CONCLUSIONS: The reporting of benefits and harms was not balanced and changed markedly over time. Knowledge of increased risk of thrombosis existed early on, but the harms came into focus too late, when the drug was already withdrawn, and when tens of thousands of patients had been harmed unnecessarily. This article was published in Eur J Clin Pharmacol and referenced in Journal of Tissue Science & Engineering

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 6th International Conference on Tissue Engineering and Regenerative Medicine
    August 23-24 , 2017 San Francisco, California ,USA
  • 8th International Conference on Tissue Science and Regenerative Medicine
    September 11-12, 2017 Singapore City, singapore
  • 9th Annual Conference on Stem Cell and Regenerative Medicine
    Sep 25-26, 2017 Berlin, Germany
  • 10th World Congress on Stem Cell and Biobanking
    October 23-24, 2017 Osaka, Japan

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords